| Item Type | Name |
|
Concept
|
Carcinoma, Papillary
|
|
Concept
|
Carcinoma, Squamous Cell
|
|
Concept
|
Carcinoma
|
|
Concept
|
Carcinoma in Situ
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Carcinoma, Transitional Cell
|
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
|
Concept
|
Adrenocortical Carcinoma
|
|
Concept
|
Carcinoma, Medullary
|
|
Academic Article
|
High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
|
|
Academic Article
|
Human renal cancer carcinogenesis: a review of recent advances.
|
|
Academic Article
|
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
|
|
Academic Article
|
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
|
|
Academic Article
|
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
|
|
Academic Article
|
Overcoming cellular senescence in human cancer pathogenesis.
|
|
Academic Article
|
Expression of bcl-2 and bcl-X in bladder cancer.
|
|
Academic Article
|
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.
|
|
Academic Article
|
Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.
|
|
Academic Article
|
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
|
|
Academic Article
|
A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.
|
|
Academic Article
|
Cytokine therapy in metastatic renal cancer.
|
|
Academic Article
|
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.
|
|
Academic Article
|
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
|
|
Academic Article
|
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
|
|
Academic Article
|
Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
|
|
Academic Article
|
Gemcitabine doublets in advanced urothelial cancer.
|
|
Academic Article
|
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
|
|
Academic Article
|
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Renal cancer immunotherapy: a ray of hope or regression to the mean?
|
|
Academic Article
|
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
|
|
Academic Article
|
A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.
|
|
Academic Article
|
Acute bilateral abducens paralysis due to oxaliplatin.
|
|
Academic Article
|
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma.
|
|
Academic Article
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
|
|
Academic Article
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
|
Academic Article
|
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
|
|
Academic Article
|
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
|
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
|
|
Academic Article
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
|
Academic Article
|
A Phase II study of oxaliplatin in urothelial cancer.
|
|
Academic Article
|
The role of systemic chemotherapy in the treatment of kidney cancer.
|
|
Academic Article
|
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
|
|
Academic Article
|
Targeted agents for the treatment of advanced renal cell carcinoma.
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling.
|
|
Academic Article
|
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
|
|
Academic Article
|
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
|
|
Academic Article
|
Sorafenib in advanced clear-cell renal-cell carcinoma.
|
|
Academic Article
|
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
|
|
Academic Article
|
Sunitinib--a new standard of care for metastatic renal cell carcinoma.
|
|
Academic Article
|
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Therapeutic options for variant renal cancer: a true orphan disease.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
|
|
Academic Article
|
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
|
|
Academic Article
|
The role of chemotherapy in upper tract urothelial carcinoma.
|
|
Academic Article
|
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study.
|
|
Academic Article
|
Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy.
|
|
Academic Article
|
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
|
|
Academic Article
|
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
|
|
Academic Article
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
|
Academic Article
|
New therapeutic options for renal cell carcinoma.
|
|
Academic Article
|
Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial.
|
|
Academic Article
|
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
|
|
Academic Article
|
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
|
|
Academic Article
|
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
|
|
Academic Article
|
Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses.
|
|
Academic Article
|
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
|
|
Academic Article
|
Prognostic factors in localized renal cell cancer.
|
|
Academic Article
|
Bevacizumab and everolimus in renal cancer: a rational way forward.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
|
|
Academic Article
|
Effective therapy for metastatic renal cancer, whither to now.
|
|
Academic Article
|
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
|
|
Academic Article
|
Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
|
|
Academic Article
|
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
|
|
Academic Article
|
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
|
|
Academic Article
|
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
|
|
Academic Article
|
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.
|
|
Academic Article
|
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Pazopanib in renal cell carcinoma.
|
|
Academic Article
|
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
|
|
Academic Article
|
Increased p16 levels correlate with pRb alterations in human urothelial cells.
|
|
Academic Article
|
Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.
|
|
Academic Article
|
Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
|
|
Academic Article
|
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
|
Academic Article
|
A molecular classification of papillary renal cell carcinoma.
|
|
Academic Article
|
Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
|
|
Academic Article
|
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
|
|
Academic Article
|
A phase II study of depsipeptide in refractory metastatic renal cell cancer.
|
|
Academic Article
|
Angiogenesis inhibition in non-clear cell renal cancer.
|
|
Academic Article
|
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
|
|
Academic Article
|
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
|
|
Academic Article
|
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
|
|
Academic Article
|
Renal cancer therapeutics: now what?
|
|
Academic Article
|
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
|
|
Academic Article
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
|
|
Academic Article
|
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
|
|
Academic Article
|
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Predictive markers in advanced renal cell carcinoma.
|
|
Academic Article
|
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
|
|
Academic Article
|
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
|
|
Academic Article
|
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
|
|
Academic Article
|
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
|
|
Academic Article
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Maturing of renal cancer therapeutics.
|
|
Academic Article
|
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
|
|
Academic Article
|
Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder.
|
|
Academic Article
|
Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?
|
|
Academic Article
|
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
|
|
Academic Article
|
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
|
|
Academic Article
|
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
|
|
Academic Article
|
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
|
|
Academic Article
|
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
|
|
Academic Article
|
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
|
|
Academic Article
|
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.
|
|
Academic Article
|
A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC).
|
|
Academic Article
|
Safety and efficacy of sorafenib in elderly patients (pts) =65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America.
|
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
|
Academic Article
|
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
|
|
Academic Article
|
Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.
|
|
Academic Article
|
Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.
|
|
Academic Article
|
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
|
|
Academic Article
|
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
|
|
Academic Article
|
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
|
|
Academic Article
|
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
|
|
Academic Article
|
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
|
|
Academic Article
|
Management of Urothelial Bladder Cancer: Predicting the Future.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
|
|
Academic Article
|
Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case.
|
|
Academic Article
|
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
|
|
Academic Article
|
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.
|
|
Academic Article
|
Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
|
|
Academic Article
|
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
|
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|
|
Academic Article
|
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
|
|
Academic Article
|
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.
|
|
Academic Article
|
NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases.
|
|
Academic Article
|
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
|
|
Academic Article
|
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
|
|
Academic Article
|
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
|
|
Academic Article
|
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
|